---
layout: default
title: Ambroxol Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 52
evidence_level: L5
indication_count: 0
---

# Ambroxol Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ambroxol Hydrochloride: Mucolytic Agent — TxGNN Prediction Pending

## One-Sentence Summary

Ambroxol Hydrochloride is a well-established mucolytic and expectorant agent, widely registered in Malaysia for respiratory indications such as bronchitis and chronic obstructive pulmonary disease (COPD).
However, the current Evidence Pack contains **no TxGNN-predicted new indications**, as prediction pipeline data is not yet populated for this candidate.
Due to critical data gaps in MOA, safety labelling, and prediction output, this report reflects a preliminary status only and a full repurposing assessment cannot yet be completed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Respiratory conditions (mucolytic/expectorant use; detailed NPRA text not populated in this dataset) |
| Predicted New Indication | Not available — TxGNN predictions not yet generated |
| TxGNN Prediction Score | Not available |
| Evidence Level | N/A (no prediction output) |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 20 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this Evidence Pack entry. Based on known pharmacological information, Ambroxol Hydrochloride belongs to the benzylamine class of mucolytics. It is a metabolite of bromhexine and is widely used to reduce mucus viscosity in the airways, facilitating expectoration. Its efficacy in respiratory conditions such as acute and chronic bronchitis, COPD, and asthma-associated secretion disorders has been extensively demonstrated in clinical practice.

Because TxGNN predictions have not yet been generated for this candidate, it is not possible to evaluate mechanistic connections between the original indication and any proposed new indication at this time. Ambroxol has been studied in emerging research areas — including neurological diseases (e.g., Gaucher's disease, Parkinson's disease via GBA pathway modulation) and local analgesic effects — however, none of these directions are currently supported by the prediction data in this Evidence Pack.

A complete repurposing rationale analysis should be conducted once TxGNN prediction output and DrugBank MOA data become available.

---

## Clinical Trial Evidence

Currently no related clinical trials registered in this Evidence Pack. TxGNN prediction data required before evidence retrieval can be targeted.

---

## Literature Evidence

Currently no related literature available in this Evidence Pack. TxGNN prediction data required to identify relevant publications.

---

## Malaysia Market Information

This drug holds **20 registrations** with Malaysia NPRA and is confirmed as actively marketed. However, individual registration details (authorization numbers, product names, dosage forms, and approved indication text) were not populated in the current dataset.

| Item | Status |
|------|--------|
| Malaysia NPRA Registration | ✓ Confirmed (20 licences) |
| Market Status | ✓ Marketed |
| Licence Detail Availability | Not populated in current Evidence Pack |

> To obtain full licence details, query the Malaysia NPRA product search portal directly using "AMBROXOL HYDROCHLORIDE" as the active ingredient.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note:** Both key warnings and contraindications are flagged as Blocking data gaps (DG001) in this Evidence Pack. This prevents completion of a standard S1 safety screen. Retrieval of the NPRA-registered package insert PDF is required before any safety-dependent decision can be made.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN prediction pipeline has not yet produced output for this candidate, and two blocking data gaps (package insert safety data and MOA) prevent meaningful repurposing evaluation. No evidence review, mechanistic analysis, or go/no-go recommendation is possible at this stage.

**To proceed, the following is needed:**

- **[Critical — Blocking]** Run TxGNN prediction pipeline for Ambroxol Hydrochloride to generate `predicted_indications` output
- **[Critical — Blocking]** Retrieve and parse the NPRA-registered package insert PDF to populate key warnings and contraindications (DG001)
- **[High]** Query DrugBank API for Ambroxol Hydrochloride to populate `drugbank_id`, MOA, categories, and toxicity data (DG002)
- **[Medium]** Re-query NPRA with individual licence numbers to populate product names, dosage forms, and approved indication text for the 20 registered products
- Once the above are resolved, re-run the Evidence Pack generation (target version v5) and proceed with full S1–S3 evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

